Ghrelin - TheraSource

Drug Profile

Ghrelin - TheraSource

Latest Information Update: 04 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TheraSource
  • Developer The Feinstein Institute for Medical Research; TheraSource
  • Class Peptide hormones
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Acute radiation syndrome; Stroke

Highest Development Phases

  • Preclinical Acute radiation syndrome; Stroke

Most Recent Events

  • 03 Aug 2016 Preclinical development in Stroke is ongoing in USA
  • 03 Aug 2016 Ghrelin - TheraSource is available for licensing as of 04 Aug 2016.
  • 12 May 2016 TheraSource receives a phase II SBIR grant from the National Institute of Allergy and Infectious Diseases for ghrelin development in Acute radiation syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top